CMPI Past Earnings image   This CMPI past earnings page last updated 7/20/2022
CMPI Past Earnings
PeriodPast Earnings DateGAAP
Q1 20225/12/2022-0.730
Q4 20213/29/2022-0.620
Q3 202111/12/2021-0.690
Q2 20218/12/2021-0.880
Q1 20215/13/2021-0.650
Q4 20203/29/20211.300
Q3 202011/13/2020-0.840
Q2 20209/18/2020-7.370
CMPI Past Revenue
PeriodPast Earnings DateGAAP
Q1 20225/12/2022NA
Q4 20213/29/2022NA
Q3 202111/12/2021NA
Q2 20218/12/2021NA
Q1 20215/13/2021NA
Q4 20203/29/2021NA
Q3 202011/13/2020NA
Q2 20209/18/2020NA
Quotes delayed 20 minutes

Email EnvelopeFree CMPI Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Checkmate Pharmaceuticals (CMPI) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

CMPX Past Earnings
CMRX Past Earnings
CNC Past Earnings
CNCE Past Earnings
CNMD Past Earnings
CNSP Past Earnings
CNST Past Earnings
CNTX Past Earnings
CNVY Past Earnings
COCP Past Earnings

CMPI Past Earnings Q&A

What was the best and worst CMPI past earnings results?
For Checkmate Pharmaceuticals, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?

✔️Accepted answer: The highest CMPI past earnings result in our data set was 1.300/share posted in Q4 2020, while the lowest was in Q2 2020 when CMPI posted -7.370/share.

  Suggested answer: The biggest top line earnings performance — aka revenue — quarter was in Q1 2022 when CMPI reported NA in revenue, while the quarter with the lowest revenue in our data set was Q1 2022 at NA of revenue.

  Suggested answer: There are 8 CMPI past earnings results in our data set.

On this page we presented the CMPI past earnings date information for Checkmate Pharmaceuticals. Reviewing that CMPI Past Earnings for the company, we see that the highest past earnings result in our data set was in Q4 2020, when CMPI posted gaap of 1.300/share. Meanwhile the lowest CMPI past earnings result was in Q2 2020, when CMPI posted gaap of -7.370/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q1 2022 when CMPI reported NA in revenue, while the smallest revenue quarter was Q1 2022 when CMPI reported NA in revenue.

Any self directed investor doing their due diligence on CMPI or any other given stock can benefit from researching all of the Checkmate Pharmaceuticals past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate Checkmate Pharmaceuticals past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CMPI. Thanks for visiting, and the next time you need to research CMPI past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.

Recommended: CHMG YTD Return, CLB Next Dividend Date, Funds Holding SHYD.

 

CMPI Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.